Best pharma stocks 2026, scored against 7 investor frameworks
Ten large-cap pharma names ranked by Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, and Smith. Patent cliffs, GLP-1 dynamics, and 2026 risks.
Last reviewed: · Educational only. Not investment advice.
Large-cap pharma is going through its largest single decade of strategic repositioning in two generations. The GLP-1 revenue pool, the Keytruda 2028 patent cliff, the Humira erosion already in motion, and the IRA price-negotiation framework are all reshaping the value capture across the industry simultaneously. The right way to read large-cap pharma in 2026 is to look for names whose replacement pipelines are credibly funded and whose patent calendars do not all crystallize in the same window.
The list below applies the seven investor frameworks invest-like uses on every ticker. Pharma names typically fail Smith (capital intensity), but the moat and capital-allocation pillars can pass when the patent calendar is clean. Reads come from the same documented methodology that powers per-ticker pages on the platform.
01
JNJJohnson & Johnson
Largest US pharma and medical-devices group, post the Kenvue consumer spin, with strong oncology and immunology franchises.
Buffett's framework passes on the moat and capital allocation. Munger is positive. Smith fails on capital intensity. Graham passes on dividend safety and balance sheet. Greenblatt picks it up. Lynch is fine with the story.
Frameworks that pass
Buffett
Munger
Graham
Greenblatt
Frameworks that fail
Smith
Key risk to know
Talc litigation tail. The talc settlement structure has stabilized but residual exposure remains a multi-year question.
Diversified large-cap pharma, post-COVID-revenue collapse, with the Seagen oncology acquisition extending the long-term pipeline.
Graham passes on cheapness post-dislocation. Greenblatt picks it up on Magic Formula. Lynch likes the recovery story. Buffett's framework is cautious on the post-Seagen leverage. Smith fails. Munger is mixed.
Frameworks that pass
Graham
Greenblatt
Lynch
Frameworks that fail
Smith
Buffett (leverage)
Key risk to know
Loss-of-exclusivity wave from 2025 to 2030. Eliquis, Ibrance, Vyndaqel, and Xeljanz all face material patent erosion.
Large-cap pharma with the Keytruda oncology franchise (the largest single drug by revenue globally) plus animal-health and HPV-vaccine franchises.
Buffett's framework passes on the Keytruda moat (until 2028 patent cliff). Munger is positive on capital allocation. Greenblatt picks it up. Graham is mixed. Smith fails. Fisher passes on R&D.
Frameworks that pass
Buffett
Munger
Greenblatt
Fisher
Frameworks that fail
Smith
Key risk to know
Keytruda 2028 LOE. The Keytruda US patent loss in 2028 is the single largest single-drug patent event in pharma history.
Largest pharma by market capitalization, with the Mounjaro and Zepbound GLP-1 franchise driving extraordinary growth and a deep diabetes and obesity pipeline.
Fisher and Munger pass strongly on R&D and franchise quality. Buffett's framework reads the moat positively but the valuation is full. Lynch fails on PEG at the current multiple. Graham fails on multiple. Smith is borderline.
Frameworks that pass
Buffett
Munger
Fisher
Frameworks that fail
Graham
Lynch (PEG)
Key risk to know
GLP-1 competition. Manufacturing capacity, generics in early 2030s, and orals (Lilly's own orforglipron, NVO's amycretin) all compress the long-term thesis.
Large-cap pharma navigating the Humira loss-of-exclusivity, with Skyrizi and Rinvoq immunology franchises plus aesthetics (Botox) and oncology.
Graham passes on dividend yield. Greenblatt picks it up. Buffett's framework is positive on the Skyrizi-Rinvoq economics. Munger is positive on capital allocation. Smith fails. Lynch is fine with the story.
Frameworks that pass
Graham
Greenblatt
Buffett
Munger
Frameworks that fail
Smith
Key risk to know
Humira biosimilar erosion pace, and the Skyrizi-Rinvoq replacement curve. The bull case requires the replacement to materially outpace the cliff.
Large-cap pharma post the Celgene integration, with Opdivo, Eliquis, and a growing post-LOE pipeline including Karuna's KarXT (Cobenfy) in schizophrenia.
Graham passes on cheapness and dividend coverage. Greenblatt picks it up. Lynch likes the post-LOE recovery story. Buffett's framework is cautious on the post-Karuna leverage. Smith fails. Munger is mixed.
Frameworks that pass
Graham
Greenblatt
Lynch
Frameworks that fail
Smith
Buffett (leverage)
Key risk to know
Eliquis and Opdivo LOE convergence. Both core franchises face material patent and competitive erosion in the next 3 to 5 years.
UK-listed (US ADR) large-cap pharma with leading positions in oncology (Tagrisso, Imfinzi, Enhertu via Daiichi partnership) plus respiratory and cardiovascular.
Fisher passes on R&D productivity. Buffett's framework is positive on the oncology pipeline. Munger is positive. Greenblatt picks it up. Smith is borderline. Graham fails on multiple. Lynch is fine with the story.
Frameworks that pass
Buffett
Munger
Fisher
Greenblatt
Frameworks that fail
Graham
Key risk to know
Enhertu pricing and partnership dynamics with Daiichi Sankyo. The Enhertu franchise is shared, and the future indications mix determines the value capture.
Swiss-listed (US ADR) large-cap pharma post the Sandoz generics spin, with focused innovation pharma across cardiovascular, oncology, and immunology.
Buffett's framework passes on the post-spin focus. Munger is positive. Smith improves on the lower capital intensity post-spin. Greenblatt picks it up. Graham is mixed on multiple. Lynch is fine with the focused story.
Frameworks that pass
Buffett
Munger
Greenblatt
Frameworks that fail
Smith (still capital intensive)
Graham
Key risk to know
Entresto and Cosentyx LOE pace. Both major franchises face material patent erosion through 2027 to 2030.
UK-listed (US ADR) pharma and vaccines group post the Haleon consumer spin, with shingles (Shingrix), HIV (ViiV), and respiratory franchises.
Graham passes on cheapness. Greenblatt picks it up. Buffett's framework is mixed on the post-Zantac litigation overhang. Smith fails. Lynch is fine with the recovery story. Munger is cautious on management track record.
Frameworks that pass
Graham
Greenblatt
Frameworks that fail
Smith
Munger
Key risk to know
Zantac litigation finalization and Shingrix demand normalization. Both have been overhangs through 2024 to 2025.
Danish-listed (US ADR) pharma with the dominant GLP-1 franchise (Ozempic, Wegovy) and a deep diabetes and obesity pipeline.
Fisher and Munger pass strongly on the GLP-1 franchise and R&D culture. Buffett's framework reads the moat positively. Smith is borderline on ROCE. Graham fails on multiple. Lynch fails on PEG. Greenblatt is mixed.
Frameworks that pass
Buffett
Munger
Fisher
Frameworks that fail
Graham
Lynch (PEG)
Key risk to know
GLP-1 supply chain and Lilly tirzepatide competition. Manufacturing capacity has been the binding constraint and competitive pressure from Lilly is accelerating.
The ten names above were drawn from the largest US-listed and US-ADR large-cap pharma companies by market capitalization, weighted toward names with documented commercial-stage portfolios and the deepest coverage on invest-like. The seven frameworks are documented in full at the methodology page.
The all-pass consensus signal is benchmarked over five years against the S&P 500 at the benchmarks page. Pharma names rarely hit the all-seven bar; the relevant signal is 4-of-7 with the Smith failure being structural. Educational only, never investment advice.
Frequently asked questions
How were these 10 pharma stocks selected?
From the largest US-listed and US-ADR large-cap pharma companies by market capitalization, weighted toward names with the deepest coverage on invest-like.
How does the pharma patent cliff affect framework reads?
Patent-loss exposure compresses the Buffett moat read (the durability pillar weakens) and the Graham read (earnings stability suffers). Names with clean replacement pipelines (LLY, NVO, MRK) score better than those entering a multi-year LOE wave.
What is the GLP-1 demand impact across pharma?
GLP-1 obesity-and-diabetes drugs are creating a once-in-a-generation revenue pool for LLY and NVO. They also create competitive pressure on cardiovascular, cardiometabolic, and obesity-adjacent franchises at other names.
What are the seven investor frameworks?
Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, and Smith. Full definitions are at the methodology page.
Are these buy recommendations?
No. This is educational analysis only.
How often is this list updated?
Per-ticker scoring updates daily. This listicle is reviewed quarterly.
Where can I see the full Buffett verdict on each name?
Each entry links to /buffett/[ticker]/ where the full five-pillar verdict is written out.
Educational only. Nothing on this page constitutes investment advice. Framework reads represent the opinion of invest-like. Past performance does not guarantee future results.
Best pharma stocks 2026, scored against 7 investor frameworks · invest-like